Malignant Giant Cell Tumor of Bone: A Study of Clinical, Pathological, and Prognostic Profile from One Single Center.

Jingtian Shi, Xin Sun, Jichuan Wang, Haijie Liang, Xingyu Liu, Yi Yang, Xiaodong Tang, Wei Guo

Abstract read

In one paragraph

Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Giant Cell Tumor of Bone: Biology, Pathophysiology, and Histopathology in the Era of H3F3A.Biomedicines · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jingtian ShiMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing 100044, China.ORCID 0000-0002-0531-2850

Xin SunMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing 100044, China.

Jichuan WangMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing 100044, China.ORCID 0009-0005-7194-0192

Haijie LiangMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing 100044, China.

Xingyu LiuMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing 100044, China.

Yi YangMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing 100044, China.

Xiaodong TangMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing 100044, China.

Wei GuoMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing 100044, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant giant cell tumor of bone (GCTB) is a rare malignant bone tumor. This analysis was conducted on patients with malignant GCTB at our center. The clinical, demographic, and prognostic characteristics were evaluated and compared. During 1 January 2015 to 31 December 2022, fifty patients were included in the study, which made up 3.3% of the contemporary GCTB patients. The clinical characteristics were comparable between the 24 patients with primary malignant GCTB (PMGCTB) and 26 patients with secondary malignant GCTB (SMGTCB). The tumor location was mainly at the axial and pelvic region (70%) and differed between the two types (

Indexed as

axial bonechemotherapydenosumabH3F3Amalignant GCTBpelvisprimarysecondary

Identifiers

PMID41007156

DOI10.3390/bioengineering12090911

PMCPMC12467924

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.